- Home
- REX vs ORIC Comparison
REX vs ORIC Comparison
Compare REX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | ORIC |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | REX | ORIC |
|---|---|---|
| Price | $33.99 | $10.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $25.00 | $19.73 |
| AVG Volume (30 Days) | 152.5K | ★ 1.8M |
| Earning Date | 12-04-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $650,756,000.00 | N/A |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $17.11 | N/A |
| P/E Ratio | $22.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.73 | $3.90 |
| 52 Week High | $36.50 | $14.93 |
Technical Indicators
Market Signals| Indicator | REX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 50.47 |
| Support Level | $33.15 | $11.52 |
| Resistance Level | $35.22 | $12.61 |
| Average True Range (ATR) | 0.90 | 0.88 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 72.74 | 50.24 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.